CoChat
Sign Up
Cited by 4,729Allergic Rhinitis and SensitizationAsthma and respiratory diseasesFood Allergy and Anaphylaxis Research

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Open access
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E. +88 more·2008·Allergy
DOI 10.1111/j.1398-9995.2007.01620.x
Open this paper in CoChat — free accountOpen PDF

Abstract

short form 36 questions; SIGN, Scottish intercollegiate network;

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1398-9995.2007.01620.x

Cites

2261 of 2261 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The absence of an IgE-mediated immune response differentiates vasomotor from allergic forms of rhinitis.

    “The absence of an IgE-mediated immune response differentiates vasomotor from allergic forms of rhinitis.101”

    From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [101]

    The Introduction (§2.1; page unavailable) associates allergic rhinitis with an IgE-mediated response. The paper places idiopathic rhinitis, sometimes called “vasomotor rhinitis,” among nonallergic conditions, but does not explicitly establish absence of IgE as its distinguishing criterion. It also cautions that vasomotor symptoms can occur in both allergic and nonallergic rhinitis. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Some patients have negative SPT or serum specific IgE despite a clinical history suggestive of allergic rhinitis and meeting ARIA clinical criteria.

    “However, some patients have negative SPT or serum sIgE despite a clinical history suggestive of AR and meeting ARIA clinical criteria.101,300”

    From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [101]

    Section 6.3.3 states that absence of serum-specific IgE does not preclude symptoms, and section 6.3.7 discusses patients with negative skin tests and serum-specific IgE. The ‘Diagnosis of allergic rhinitis’ section describes typical symptoms, but also says diagnosis depends on concordance between the history and diagnostic tests; it does not establish that patients with negative tests meet ARIA diagnostic criteria. Page numbers are unavailable in our copy. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

  • Most patients with asthma, both allergic and non-allergic, also have rhinitis, whereas 10% to 40% of patients with AR have comorbid asthma.

    “Most patients with asthma (both allergic and non-allergic) also have rhinitis, whereas 10% to 40% of patients with AR have comorbid asthma.101,1167”

    From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [101]

    Section 9.1.2 says the majority of patients with asthma experience rhinitis symptoms. Section 9.1.1 gives the 10%–40% asthma prevalence for patients with rhinitis generally, not specifically for patients with allergic rhinitis (AR), so the narrower population in the claim is not fully supported. The supplied copy gives no page numbers for these passages. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • LTRAs are the only class of medications specifically described in the 2008 AR management guide and full ARIA report as effective for both asthma and AR.

    “In fact, the LTRAs are the only class of medications specifically described in the 2008 AR management guide for primary care physicians, and in the full ARIA report, as effective for both asthma and AR.101,1814”

    From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [101]

    Table 24 in section 7.8.2 describes antileukotrienes as “Effective on asthma and rhinitis,” and the Pharmacodynamics section reports that montelukast improved nasal and bronchial symptoms. Our copy does not establish that LTRAs are the only medication class so described, or verify what the separate primary-care management guide says. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • Intranasal corticosteroids have a potent anti-inflammatory effect and have proven effective in treating NO in both rhinitis and rhinosinusitis.

    “Intranasal corticosteroids (INCs) (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, triamcinolone) have a potent antiinflammatory effect and have proven to be effective in treating NO in both rhinitis and rhinosinusitis, as shown in several international consensus statements [127-131].”

    From Position Paper on Nasal Obstruction: Evaluation and Treatment (2018) · cites this paper as [129]

    Section 7.2.4 (page unavailable) describes intranasal glucocorticosteroids as highly effective for rhinitis and recommends them as first-line treatment when nasal congestion is present. Its table describes potent pharmacologic action, but the passages found do not establish effectiveness for nasal obstruction in rhinosinusitis. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

1 retracted

Flagged first, then by citations

6 of the 2267 references couldn’t be matched to a known paper.

Research works printed but not linked: 24

  1. Barbara P. Yawn has received research funding from Astra Zeneca, Schering-Plough, GlaxoSmithKline and Merck for inves- tigator initiated grants in the area of respiratory health. She has also acted as a paid consultant to Schering-Plough, Astra Zeneca, Merck and Pfizer in the area of respiratory health. Arzu Yorgancioglu has contractually researched with AstraZe- neca, Novartis, Boehringer-Ingelheim/Pfizer, Sanofi-Aventis and lecturers with AstraZeneca, Novartis, Boehringer-Ingelheim, Sano- fi-Aventis, Abdi-Ibrahim and Merck. The following authors declare no conflicts of interest: Nikolaı¨Khaltaev Alvaro A. Cruz Judah Denburg Wytske J. Fokkens Alkis Togias Carlos E. Baena-Cagnani G. Walter Canonica Ioana Agache Nadia Aı¨t-Khaled Claus Bachert Philippe-J. Bousquet Paulo Camargos Yuzhi Chen Pascal Demoly Habib Douagui Omer Kalayci You-Young Kim Piotr Kuna Lan Thi Tuyet Le Catherine Lemiere Jing Li Richard F. Lockey Sandra Mavale-Manuel Yousser Mohammad Joaquim Mullol Robert Naclerio Robyn E. OÕHehir Ken Ohta Solange Ouedraogo Susanna Palkonen Giovanni Passalacqua Ruby Pawankar Todor A. Popov Klaus F. Rabe Jose´Rosado-Pinto F. Estelle R. Simons Elina Toskala Erkka Valovirta Paul van Cauwenberge De-Yun Wang Magnus Wickman Osman M. Yusuf Heather Zar Review Group: Eric D. Bateman has served on or currently serves on advisory board for Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoS- mithKline, Kyowa Hakko, Merck, Novartis, Nycomed, Pfizer and Sanofi-Aventis and has received honoraria for educational activities organized by Altana/Nycomed, AstraZeneca, Boehringer Ingel- heim, GlaxoSmithKline and Pfizer. His institution has received funding for research from Almirall, Altana, AstraZeneca, Boehrin- ger Ingelheim, Chiesi, GlaxoSmithKline, Kyowa Hakko, Lilly, Merck, Novartis, Nycomed, Pfizer, Sanofi-Aventis and Schering- Plough. He chairs a safety committee for Hofflman le Roche, Peter Burney has received lecture fees from AstraZeneca.
  2. Togias A. Rhinitis and asthma: evi- dence for respiratory system integra- tion. J Allergy Clin Immunol. 2003;111:1171-1183; quiz 84.
  3. Lenfant C. Introduction. In: Corren J, Togias A, Bousquet J, editors. Upper and lower respiratory disease lung biology in health and disease, Vol. 181. NY: Marcel Dekker, 2004:iii-iv.
  4. Bachert C, Vignola AM, Gevaert P, Leynaert B, Van Cauwenberge P, Bousquet J. Allergic rhinitis, rhinosi- nusitis, and asthma: one airway dis- ease. Immunol Allergy Clin North Am 2004;24:19-43.
  5. Wreesmann VB, Fokkens WJ, Knegt PP. Refractory chronic sinusi- tis: evaluation of symptom improve- ment after DenkerÕs procedure. Otolaryngol Head Neck Surg 2001;125:495-500.
  6. Riediker M, Monn C, Koller T, Stahel WA, Wuthrich B. Air pollu- tants enhance rhinoconjunctivitis symptoms in pollen-allergic individu- als. Ann Allergy Asthma Immunol 2001;87:311-318.
  7. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhino- conjunctivitis Quality of Life Ques- tionnaire. J Allergy Clin Immunol 1999;104:364-369.
  8. Cuel B, Wamboldt M, Borish L, Kennedy S, Crystal-Peters J. Eco- nomic consequences of comorbid depression, anxiety, and allergic rhi- nitis [In Process Citation]. Psychoso- matics 1999;40:491-496. 1058.
  9. Sundberg R, Toren K, Hoglund D, Aberg N, Brisman J. Nasal symp- toms are associated with school per- formance in adolescents. J Adolesc Health 2007;40:581-583. 1112.
  10. Rice D, Hodgson T, Kopstein A. The economic cost of illness: a replication and update. Heath Care Financ Rev 1985;7:61-80. 1127.
  11. Spaeth J, Schultze V, Klimek L, Lengersdorf A, Mosges R. Azelas- tine reduces histamine-induced swell- ing of nasal mucosa. ORL J Otorhinolaryngol Relat Spec 1996;58:157-163. 1163. Pepys J. Skin testing. Br J Hosp Med 1975;14:412. 1164.
  12. Eggleston PA, Ansari AA, Ziemann B, Adkinson N Jr, Corn M. Occu- pational challenge studies with labo- ratory workers allergic to rats. J Allergy Clin Immunol 1990;86:63-72. 1320.
  13. Katotomichelakis M, Balatsouras D, Tripsianis G, Tsaroucha A, Homsioglou E, Danielides V. Nor- mative values of olfactory function testing using the ÔsniffinÕ sticksÕ. Laryngoscope 2007;117:114-120. 1414.
  14. McTavish D, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and ther- apeutic potential Drugs 1989;38:778- 800. 1456.
  15. McNeely W, Wiseman LR. Intrana- sal azelastine. A review of its efficacy in the management of allergic rhinitis [published erratum appears in Drugs 1999;57(1):8]. Drugs 1998;56:91-114. 1488.
  16. Johnson DA, Hricik JG. The phar- macology of alpha-adrenergic decon- gestants. Pharmacotherapy 1993;13:110S-115S; discussion 43S- 46S. 1603.
  17. Morais-Almeida M, Gaspar A, Pires G, Prates S, Rosado-Pinto J. Links between rhinitis and asthma. Allergy Asthma Proc 2008 (in press). 1938.
  18. Rajakukasingam K, Durham S. Comparative pathogenesis of upper and lower airway allergic diseases. In: Corren J, Togias A, Bousquet J, Lenfant C, editors. Upper and lower respiratory disease lung biology in health and disease, Vol. 181. NY: Marcel Dekker, 2004:139-174. 1978.
  19. Chakir J, Laviolette M, Boutet M, Laliberte R, Dube J, Boulet LP. Lower airways remodeling in non- asthmatic subjects with allergic rhini- tis. Lab Invest 1996;75:735-744. 1981.
  20. Bonini S, Bonini S. Studies of allergic conjunctivitis. Chibret Int J 1987;5:12-22. 2084.
  21. Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjuncti- vitis. Eye 2004;18:345-351. 2085.
  22. Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratocon- junctivitis in Thailand. Asian Pac J Allergy Immunol 2003;21:25-30. 2086. Ukponmwan CU. Vernal keratocon- junctivitis in Nigerians: 109 consecu- tive cases. Trop Doct 2003;33:242- 245. 2087.
  23. Keil T, Kulig M, Simpson A, Cus- tovic A, Wickman M, Kull I, et al. European birth cohort studies on asthma and atopic diseases: I. Com- parison of study designs -a GALEN initiative. Allergy 2006;61:221-228. 2174.
  24. Osborne M, Reponen T, Adhikari A, Cho SH, Grinshpun SA, Levin L, et al. Specific fungal exposures, aller- gic sensitization, and rhinitis in in- fants. Pediatr Allergy Immunol 2006;17:450-457. 2188.

Cited by

Sorted by citations

Related

Authors
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., Agache, I., Aït‐Khaled, N., Bachert, C., Blaiss, M. S., Bonini, S., Boulet, L. ‐., Bousquet, P. ‐., Camargos, P., Carlsen, K. ‐., Chen, Y., Custovic, A., Dahl, R., Demoly, P., Douagui, H., Durham, S. R., Van Wijk, R. G., Kalayci, O., Kaliner, M. A., Kim, Y. ‐., Kowalski, M. L., Kuna, P., Le, L. T. T., Lemiere, C., Li, J., Lockey, R. F., Mavale‐Manuel, S., Meltzer, E. O., Mohammad, Y., Mullol, J., Naclerio, R., O’Hehir, R. E., Ohta, K., Ouedraogo, S., Palkonen, S., Papadopoulos, N., Passalacqua, G., Pawankar, R., Popov, T. A., Rabe, K. F., Rosado‐Pinto, J., Scadding, G. K., Simons, F. E. R., Toskala, E., Valovirta, E., Van Cauwenberge, P., Wang, D. ‐., Wickman, M., Yawn, B. P., Yorgancioglu, A., Yusuf, O. M., Zar, H., Annesi‐Maesano, I., Bateman, E. D., Kheder, A. B., Boakye, D. A., Bouchard, J., Burney, P., Busse, W. W., Chan‐Yeung, M., Chavannes, N. H., Chuchalin, A., Dolen, W. K., Emuzyte, R., Grouse, L., Humbert, M., Jackson, C., Johnston, S. L., Keith, P. K., Kemp, J. P., Klossek, J. ‐., Larenas‐Linnemann, D., Lipworth, B., Malo, J. ‐., Marshall, G. D., Naspitz, C., Nekam, K., Niggemann, B., Nizankowska‐Mogilnicka, E., Okamoto, Y., Orru, M. P., Potter, P., Price, D., Stoloff, S. W., Vandenplas, O., Viegi, G., & Williams, D.
Affiliations
  • Inserm (FR)
  • McMaster University (CA)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • National Institute of Allergy and Infectious Diseases (US)
  • Charité – Universitätsmedizin Berlin (DE)
  • Universidad Católica de Córdoba (AR)
  • World Health Organization (CH)
  • Transilvania University of Brașov (RO)
  • Ghent University Hospital (BE)
  • University of Tennessee Health Science Center (US)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • Universidade Federal de Minas Gerais (BR)
  • University of Oslo (NO)
  • Capital Institute of Pediatrics (CN)
  • Aarhus University Hospital (DK)
  • Imperial College London (GB)
  • Hacettepe University (TR)
  • Institute for Asthma and Allergy (US)
  • Seoul National University Hospital (KR)
  • Medical University of Lodz (PL)
  • University of Medicine and Pharmacy at Ho Chi Minh City (VN)
  • First Affiliated Hospital of Guangzhou Medical University (CN)
  • University of South Florida (US)
  • University of California San Diego (US)
  • Latakia University (SY)
  • Hospital Clínic de Barcelona (ES)
  • University of Chicago (US)
  • The Alfred Hospital (AU)
  • Teikyo University (JP)
  • European Federation of Allergy and Airways Diseases Patients Associations (BE)
  • National University of Singapore (SG)
  • University of Genoa (IT)
  • Nippon Medical School (JP)
  • Medical University of Sofia (BG)
  • Leiden University Medical Center (NL)
  • Hospital de Dona Estefânia (PT)
  • University College London (GB)
  • University of Manitoba (CA)
  • Hôpital Arnaud de Villeneuve (FR)
  • University of Minnesota Rochester (US)
  • University of Cape Town (ZA)
  • Tunis University (TN)
  • University of Ghana (GH)
  • University of Wisconsin–Madison (US)
  • University of British Columbia (CA)
  • Augusta University (US)
  • Vilnius University (LT)
  • Université Paris-Sud (FR)
  • University of Dundee (GB)
  • Université de Poitiers (FR)
  • University of Mississippi (US)
  • Chiba University (JP)
  • University of Aberdeen (GB)
  • University of Nevada, Reno (US)
  • UCLouvain (BE)
  • Istituto di Fisiologia Clinica (IT)
  • University of North Carolina at Chapel Hill (US)
ORCID
Venue
Allergy
Publisher
Wiley
Published
2008-03-07
Volume
63
Issue
s86
Pages
8-160
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
DOI
10.1111/j.1398-9995.2007.01620.x
OpenAlex
W2164132449
Cited by
4,729
References
2,267
Citations by year
2026: 135 · 2025: 172 · 2024: 211 · 2023: 230 · 2022: 242 · 2021: 287 · 2020: 292 · 2019: 279 · 2018: 278 · 2017: 301 · 2016: 307 · 2015: 302 · 2014: 293 · 2013: 300 · 2012: 274
FWCI
171.93
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Allergy (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • HAL (submittedVersion)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
  • Digital Access to Libraries (submittedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • ANU Open Research (Australian National University) (submittedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
  • Industry Canada
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
allergic rhinitis, asthma, allergic rhinitis and asthma, ARIA guidelines, quality of life, health-related quality of life, SF-36
MeSH terms
Adolescent, Asthma, Child, Rhinitis, Allergic, Seasonal, Humans, Rhinitis, Allergic, Perennial, Risk Factors, Global Health, World Health Organization, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review